期刊文献+

吡非尼酮在中国健康受试者单剂量及多剂量的药动学研究 被引量:4

Pharmacokinetics of Pirfenidone after a Single Dose and Multiple-dose Administration in Chinese Healthy Volunteers
原文传递
导出
摘要 目的 研究吡非尼酮在中国健康受试者单剂量及多剂量的药动学特征。方法 12名健康受试者随机分成低、中、高3个剂量组(200、400、600 mg)进行单次口服给药,其中400 mg组为多次给药组,连续给药5 d,每天3次,采集第3、4、5天早晨服药前和第5日服药后12 h内血样;采用高效液相色谱-质谱联用测定法测定血浆中吡非尼酮的浓度,并采用DAS程序对试验数据进行处理,计算药动学参数。结果 单次口服200、400、600 mg吡非尼酮的主要药动学参数ρmax分别为(5.00±1.42)、(9.43±2.74)、(14.14±3.36)mg·L-1,tmax分别为(0.57±0.33)、(0.60±0.30)、(0.60±0.38)h,t1/2分别为(2.16±0.77)、(2.15±0.75)、(2.01±0.76)h,AUC(0-∞)分别为(13.87±7.79)、(29.26±12.02)、(45.85±20.25)mg·h·L-1,AUC0-12分别为(13.27±7.08)、(27.92±10.56)、(43.98±18.14)mg·h·L-1。多次给药400 mg后的药动学参数ρmax为(9.46±2.77)mg·L-1,ρmin为(1.14±1.11)mg·L-1,tmax为(0.52±0.34)h,t1/2为(1.93±0.63)h,AUC0-∞为(26.74±13.49)mg·h·L-1,AUC0-12为(25.79±12.34)mg·h·L-1,AUCss为(23.53±10.59)mg·h·L-1。结论 吡非尼酮在200~600 mg内ρmax与AUC与剂量线性关系良好,药动学参数与文献值较为一致。 OBJECTIVE To study the pharmacokinetics of pirfenidone in Chinese healthy volunteer after a single dose and multiple-dose administration.METHODS Twelve Chinese healthy volunteers were randomly divided into low,medium and high dose groups( 200,400,600 mg).The multiple-dose group was administrated with pirfenidione 400 mg three times daily for 5 d.Intensive blood sampling was performed from 12 volunteers within 12 h after the single dosing and the last dose of the multiple dosing.HPLCMS / MS was used to determine the plasma concentrations of pirfenidone.The pharmacokinetic parameters were calculated by DAS software.RESULTS The main pharmacokinetic parameters of pirfenidone after single-dose administration of 200,400,600 mg qd as follows:ρmaxwere( 5.00 ± 1.42),( 9.43 ± 2.74) and( 14.14 ± 3.36) mg·L-1; tmaxwere( 0.57 ± 0.33),( 0.60 ± 0.30) and( 0.60 ±0.38) h; t1 /2were( 2.16 ± 0.77),( 2.15 ± 0.75) and( 2.01 ± 0.76) h; AUC0-∞were( 13.87 ± 7.79),( 29.26 ± 12.02) and( 45.85 ±20.25) mg·h·L-1; AUC0-12 were 为( 13.27 ± 7.08),( 27.92 ± 10.56) and( 43.98 ± 18.14) mg·h·L-1,respectively.The main pharmacokinetic parameters after 400 mg tid for 5 d were as follows:ρmaxwas( 9.46 ± 2.77) mg·L-1,ρminwas( 1.14 ± 1.11)mg·L-1,tmaxwas( 0.52 ± 0.34) h,t1 /2was( 1.93 ± 0.63) h,AUC0-∞was( 26.74 ± 13.49) mg · h · L-1,AUC0-12was( 25.79 ± 12.34) mg·h·L-1,AUCsswas( 23.53 ± 10.59) mg· h· L-1.CONCLUSION The pharmacokinetic parameters of pirfenidone show that ρmaxand AUC were linear in the dose range from 200-600 mg and the pharmacokinetic parameters were similar as reference.
出处 《中国药学杂志》 CAS CSCD 北大核心 2015年第13期1134-1137,共4页 Chinese Pharmaceutical Journal
基金 广东省重大科技专项资助项目(2011A080300003) 广州市脑科医院广州市医学重点学科建设项目子项目资助项目(GBH2014-ZD07)
关键词 吡非尼酮 高效液相色谱-质谱联用 药动学 pirfenidone HPLC-MS / MS pharmacokinetics
  • 相关文献

参考文献6

  • 1SHI S, WU J, CHEN H, et al. Single- and multiple-dose pharma- cokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers [ J ]. J Clin Pharmacol, 2007, 47 (10) : 1268-1276.
  • 2SHI Q, LIU X, BAI Y,et al. In vitro effects of pirfenidone on car- diac fibroblasts : Proliferaton, myofibroblast, differentiation, migra- tion and cytokine secretion [ J ]. PLoS One,2011,6 ( 11 ) : e28134.
  • 3王永升,赵小平,钟皎,陈燕,柳晓泉,王广基.HPLC-UV法测定比格犬血浆中吡非尼酮浓度及其药代动力学[J].中国药科大学学报,2006,37(2):146-149. 被引量:8
  • 4HUANG N Y, DING L, WANG J, et al. Pharmacokinetics, safety and tolerablity of pirfenidone and its major metabolite after single and multiple oral doses in healthy Chinese subjects under fed con- ditions[ J]. Drug Res ,2013, 63 ( 8 ) :388-395.
  • 5陈敏纯,王茂湖,曹青,贾艳艳,李海燕,周伦,文爱东.高效液相色谱法测定人血浆中吡非尼酮的含量[J].中国新药与临床杂志,2013,32(6):473-476. 被引量:3
  • 6WEN Y G, LIU X, HE X L,et al. Simultaneous determination of pirfenidone and its metabolite in human plasma by liquid chroma- tography-tandem mass spectrometry: Application to a pharmacoki- netic study [ J]. J Anal Toxicol,2014,38 ( 9 ) :645-652.

二级参考文献13

  • 1王永升,赵小平,钟皎,陈燕,柳晓泉,王广基.HPLC-UV法测定比格犬血浆中吡非尼酮浓度及其药代动力学[J].中国药科大学学报,2006,37(2):146-149. 被引量:8
  • 2Iyer SN,Wild JS,Schiedt MJ,et al.Dietary intake of pirfenidone ameliorates blemycin-induced lung fibrosis in hamsters[J].J Lab Clin Med,1995,125(6):779-785.
  • 3Iyer SN,Margolin SB,Hyde DM,et al.Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model[J].Exp Lung Res,1998,24(1):119-132.
  • 4Dosanjh A,Wan B,Throndset S,et al.Pirfenidone:a novel antifibrosis agent with implications for the treatment of obliterative bronchiolitis[J].Transplant Proc,1998,30(5):1 910-1 911.
  • 5Raghu G,Johnson WC,Lockhort D,et al.Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent,pirfenidone:results of a prospective,open-label phase Ⅱ study[J].Am J Respir Crit Care Med,1999,159(4):1 061-1 069.
  • 6Taniyama M,Ohbayashi S,Narita M,et al.Pharmacokinetics of an anti-fibrotic agent,pirfenidone,in hemodialysis patients[J].Eur J Clin Pharmacol,1997,52(1):77-78.
  • 7Giri SN,Wang QJ,Xie Y,et al.Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone,in mice following intravenous administration[J].Biopharm Drug Dispos,2002,23(5):203-211.
  • 8Bruss ML,Margolin SB,Giri SN.Pharmacokinetics of orally administered pirfenidone in male and female Beagles[J].J Vet Pharmacol Ther,2004,27(5):361-367.
  • 9AZUMA A, TAGUCHI Y, OGUA T, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment[J]. Respir Res, 2011, 12: 143.
  • 10NOBLE PW, ALBERA C, BRADFORD WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials[J]. Lancet, 2011, 377(9779) : 1760-1769.

共引文献9

同被引文献24

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部